Experimental evidence has demonstrated that increased DBC1 expression markedly diminishes the tumor-suppressive effects of SIRT1 in breast cancer, significantly shortening the survival of both ERα-positive and ERα-negative patients. The gene discussed is CCAR2; the disease is breast carcinoma.